share_log

Tempus AI | 8-K: Tempus Reports Second Quarter 2024 Results

Tempus AI | 8-K: Tempus Reports Second Quarter 2024 Results

Tempus AI | 8-K:Tempus 公佈 2024 年第二季度業績
美股SEC公告 ·  2024/08/07 04:07

Moomoo AI 已提取核心訊息

Tempus AI reported strong Q2 2024 results with revenue increasing 25% YoY to $166.0 million, driven by 40% growth in data licensing revenue. The company's genomics revenue grew 22.2% to $112.3 million, while data and services revenue rose 32.5% to $53.6 million.The company recorded a net loss of $552.2 million, primarily due to $493.1 million in stock compensation expense and related employer payroll taxes tied to its initial public offering. Adjusted EBITDA improved by $12.7 million QoQ to ($31.2 million). During the quarter, Tempus raised $410.7 million in gross proceeds from its IPO.Notable operational highlights include expansion into the minimal residual disease market with new assays, FDA clearance for the ECG-AF device, and establishment of a joint venture with SoftBank to enter the Japanese market. The company expects full year 2024 revenue of approximately $700 million, representing 32% annual growth.
Tempus AI reported strong Q2 2024 results with revenue increasing 25% YoY to $166.0 million, driven by 40% growth in data licensing revenue. The company's genomics revenue grew 22.2% to $112.3 million, while data and services revenue rose 32.5% to $53.6 million.The company recorded a net loss of $552.2 million, primarily due to $493.1 million in stock compensation expense and related employer payroll taxes tied to its initial public offering. Adjusted EBITDA improved by $12.7 million QoQ to ($31.2 million). During the quarter, Tempus raised $410.7 million in gross proceeds from its IPO.Notable operational highlights include expansion into the minimal residual disease market with new assays, FDA clearance for the ECG-AF device, and establishment of a joint venture with SoftBank to enter the Japanese market. The company expects full year 2024 revenue of approximately $700 million, representing 32% annual growth.
Tempus 人工智能報告稱2024年第二季度業績強勁,營業收入同比增長25%,達到16600萬,數據許可收入增長40%驅動了這一增長。公司的基因組學營業收入增長了22.2%,達到11230萬,而數據和服務營業收入增長32.5%,達到5360萬。公司錄得淨虧損55220萬,主要由於49310萬的股票補償費用和與首次公開募股相關的僱主薪資稅。調整後的EBITDA環比改善1270萬,達到(3120萬)。在這一季度,Tempus通過首次公開募股籌集了41070萬的總收入。值得注意的運營亮點包括通過新檢測擴展到微小殘留病市場,ECG-AF設備獲得FDA批准,以及與軟銀合作建立合資公司進軍日本市場。公司預計2024年全年營業收入約爲70000萬,年增長32%。
Tempus 人工智能報告稱2024年第二季度業績強勁,營業收入同比增長25%,達到16600萬,數據許可收入增長40%驅動了這一增長。公司的基因組學營業收入增長了22.2%,達到11230萬,而數據和服務營業收入增長32.5%,達到5360萬。公司錄得淨虧損55220萬,主要由於49310萬的股票補償費用和與首次公開募股相關的僱主薪資稅。調整後的EBITDA環比改善1270萬,達到(3120萬)。在這一季度,Tempus通過首次公開募股籌集了41070萬的總收入。值得注意的運營亮點包括通過新檢測擴展到微小殘留病市場,ECG-AF設備獲得FDA批准,以及與軟銀合作建立合資公司進軍日本市場。公司預計2024年全年營業收入約爲70000萬,年增長32%。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息